secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0000917520-26-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra Q1 2026: Adj. EPS $0.54 vs $0.41; raises FY adj. EPS guidance to $2.40-$2.50
--------------------------------------------------------------------------------

- Q1 revenue $391.9M (+2.4% reported; +1.3% organic). GAAP net loss $(4.6)M vs $(25.3)M prior year.
- Adjusted EPS $0.54 vs $0.41; adjusted gross margin 64.1% vs 62.2%. Adjusted EBITDA $76.2M (19.4% rev).
- Specialty Surgery rev $283.1M (+0.9% rep, -0.6% organic); Tissue Reconstruction $108.8M (+6.7% rep, +6.4% organic).
- Reaffirms FY rev guidance $1.662B-$1.702B; raises adj. EPS guidance to $2.40-$2.50 from $2.30-$2.40.
- Braintree facility on track to begin SurgiMend production by end of June for Q4 launch; PriMatrix/Durepair returning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/0000917520-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/iart-20260505.htm
  HTML page:      https://secwatch.observer/filing/0000917520-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer